Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes

Nanexa AB (STO: NANEXA), a Swedish drug delivery platform company, announced a global exclusive license and collaboration agreement with Novo Nordisk (NYSE: NVO) for the use of the PharmaShell technology…

European Commission Revokes Hansoh's Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

European Commission Revokes Hansoh’s Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer

CompanyDrug

Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC

CompanyDrug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial

CompanyDeals

Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results

CompanyDrug

CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy

CompanyDrug

Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials

CompanyDrug

Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

CompanyDrug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment

Show More